Repligen Corporation Stock News

Repligen (RGEN) reports encouraging fourth-quarter and full-year 2022 results, with sales and earnings beating estimates.

Start Time: 08:30 January 1, 0000 9:37 AM ET Repligen Corporation (NASDAQ:RGEN ) Q4 2022 Earnings Conference Call February 22, 2023, 08:30 AM ET Company Participants Tony Hunt - President and CEO Jon

Repligen (RGEN) delivered earnings and revenue surprises of 17.24% and 0.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session. FiscalNote Holdings, Inc. (NYSE: NOTE) dipped 2

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

Investors need to pay close attention to Repligen (RGEN) stock based on the movements in the options market lately.

The company is coming off a solid third quarter and is getting noticed by analysts.

The company is coming off a solid third quarter and is getting noticed by analysts.

HZNP vs. RGEN: Which Stock Is the Better Value Option?

HZNP vs. RGEN: Which Stock Is the Better Value Option?

The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at th

A 3-5 month prospect from here of RGEN share prices could reasonably range from a $156.4 low to a $190.62 high from its present $162.42 price, a +17.4% gain. 88 positions like today's in the past 5 ye

Upgrades Wolfe Research upgraded the previous rating for EQT Corp (NYSE:EQT) from Peer Perform to Outperform. EQT earned $1.04 in the third quarter, compared to $0.12 in the year-ago quarter. At the m